Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has been issued a patent. The company stated that the patent, No. US 11,628,132, marked “a significant milestone in the development of innovative treatments for androgenetic alopecia, or hair loss. This foundational patent is a crucial component of the company’s ongoing pursuit of the vast hair loss market.” According to the announcement, the technology covered by the patent focuses on increasing the efficacy of minoxidil, a widely used hair-loss treatment, used in a novel manner that could have the potential for a breakthrough solution for the millions of people around the world who deal with hair loss. The company pointed to the patent as a symbol of its commitment to better understanding hair growth and loss mechanisms. “We are thrilled to have this patent granted, as it signifies an important step forward in our mission to develop innovative solutions for health and wellness,” said Jupiter Wellness CEO Brian John in the press release. “This foundational patent lays the groundwork for our pursuit of the enormous global hair loss market. We are confident that our patented technology has the potential to greatly improve the lives of those suffering from hair loss.”
To view the full press release, visit https://ibn.fm/myIyk
About Jupiter Wellness Inc.
Jupiter Wellness is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company’s product pipeline addresses a range of conditions, including hair loss, psoriasis and vitiligo. Revenue is generated through the sales of OTC and consumer products, contract research agreements and licensing royalties. For additional information about this company, please visit www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
